Richard David Wyss, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Propensity Score | 10 | 2024 | 1908 | 1.690 |
Why?
|
| Pharmacoepidemiology | 1 | 2022 | 350 | 0.630 |
Why?
|
| Dermatitis, Atopic | 5 | 2024 | 721 | 0.610 |
Why?
|
| Hidradenitis Suppurativa | 3 | 2024 | 175 | 0.480 |
Why?
|
| Psoriasis | 4 | 2024 | 939 | 0.460 |
Why?
|
| Research Design | 5 | 2024 | 6178 | 0.400 |
Why?
|
| Computer Simulation | 7 | 2024 | 6238 | 0.360 |
Why?
|
| Vitiligo | 2 | 2022 | 97 | 0.360 |
Why?
|
| Medicare | 3 | 2024 | 6770 | 0.360 |
Why?
|
| Delivery of Health Care | 3 | 2024 | 5335 | 0.350 |
Why?
|
| Conjunctivitis | 2 | 2022 | 155 | 0.350 |
Why?
|
| Electronic Health Records | 3 | 2024 | 4811 | 0.330 |
Why?
|
| Models, Statistical | 3 | 2024 | 5077 | 0.310 |
Why?
|
| Opportunistic Infections | 2 | 2020 | 376 | 0.290 |
Why?
|
| Cohort Studies | 9 | 2023 | 41446 | 0.280 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 12456 | 0.260 |
Why?
|
| Databases, Factual | 6 | 2024 | 7956 | 0.250 |
Why?
|
| Algorithms | 4 | 2023 | 14026 | 0.220 |
Why?
|
| Conjunctivitis, Bacterial | 1 | 2022 | 22 | 0.200 |
Why?
|
| Methotrexate | 3 | 2024 | 1718 | 0.200 |
Why?
|
| Hepatitis | 1 | 2024 | 229 | 0.200 |
Why?
|
| Pemphigoid, Bullous | 1 | 2023 | 114 | 0.190 |
Why?
|
| Conjunctivitis, Allergic | 1 | 2022 | 124 | 0.180 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2024 | 267 | 0.180 |
Why?
|
| Systemic Vasculitis | 1 | 2020 | 36 | 0.170 |
Why?
|
| Alopecia Areata | 1 | 2022 | 127 | 0.170 |
Why?
|
| Scleroderma, Localized | 1 | 2020 | 87 | 0.170 |
Why?
|
| Venous Thromboembolism | 2 | 2023 | 1866 | 0.160 |
Why?
|
| Live Birth | 1 | 2022 | 511 | 0.160 |
Why?
|
| Sjogren's Syndrome | 1 | 2020 | 234 | 0.160 |
Why?
|
| Thalidomide | 1 | 2024 | 885 | 0.160 |
Why?
|
| Connective Tissue Diseases | 1 | 2020 | 285 | 0.140 |
Why?
|
| Phototherapy | 1 | 2020 | 368 | 0.140 |
Why?
|
| Peer Review | 1 | 2017 | 217 | 0.120 |
Why?
|
| Epidemiologic Research Design | 1 | 2018 | 368 | 0.120 |
Why?
|
| Likelihood Functions | 1 | 2018 | 992 | 0.120 |
Why?
|
| Natural Language Processing | 1 | 2023 | 1162 | 0.110 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2018 | 452 | 0.110 |
Why?
|
| Bacterial Infections | 1 | 2020 | 1393 | 0.100 |
Why?
|
| Humans | 26 | 2024 | 761423 | 0.100 |
Why?
|
| Tuberculosis | 1 | 2024 | 2016 | 0.090 |
Why?
|
| Biological Products | 1 | 2020 | 912 | 0.090 |
Why?
|
| Immunosuppressive Agents | 2 | 2022 | 4172 | 0.090 |
Why?
|
| Colitis, Ulcerative | 1 | 2022 | 1922 | 0.090 |
Why?
|
| Crohn Disease | 1 | 2022 | 2279 | 0.080 |
Why?
|
| Medicaid | 1 | 2022 | 2818 | 0.080 |
Why?
|
| Research | 1 | 2017 | 1977 | 0.080 |
Why?
|
| United States | 8 | 2024 | 72339 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2018 | 6343 | 0.080 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2022 | 2422 | 0.070 |
Why?
|
| Incidence | 4 | 2023 | 21341 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2020 | 23990 | 0.050 |
Why?
|
| Asthma | 1 | 2022 | 6211 | 0.050 |
Why?
|
| Logistic Models | 1 | 2018 | 13255 | 0.050 |
Why?
|
| Monte Carlo Method | 2 | 2019 | 1257 | 0.050 |
Why?
|
| Birth Certificates | 1 | 2022 | 71 | 0.050 |
Why?
|
| Obesity | 1 | 2024 | 12938 | 0.050 |
Why?
|
| Aged | 5 | 2024 | 169235 | 0.040 |
Why?
|
| Arthralgia | 1 | 2023 | 461 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2022 | 778 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 2 | 2019 | 2691 | 0.040 |
Why?
|
| Adrenergic Antagonists | 1 | 2018 | 26 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2024 | 880 | 0.040 |
Why?
|
| Time Factors | 1 | 2020 | 39975 | 0.040 |
Why?
|
| Causality | 1 | 2024 | 1243 | 0.040 |
Why?
|
| Angioedema | 1 | 2018 | 191 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2024 | 1588 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2023 | 15838 | 0.030 |
Why?
|
| Child | 4 | 2024 | 80162 | 0.030 |
Why?
|
| Gestational Age | 1 | 2022 | 3576 | 0.030 |
Why?
|
| Anticoagulants | 2 | 2019 | 4813 | 0.030 |
Why?
|
| Adolescent | 4 | 2024 | 88313 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2024 | 4354 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 1517 | 0.020 |
Why?
|
| Adult | 5 | 2024 | 221148 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 3081 | 0.020 |
Why?
|
| Young Adult | 3 | 2024 | 59207 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2019 | 4016 | 0.020 |
Why?
|
| Female | 7 | 2024 | 392581 | 0.020 |
Why?
|
| Heart | 1 | 2023 | 4405 | 0.020 |
Why?
|
| Warfarin | 1 | 2018 | 1483 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 1664 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2023 | 12330 | 0.020 |
Why?
|
| Comorbidity | 1 | 2024 | 10498 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2020 | 2497 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2022 | 9320 | 0.020 |
Why?
|
| Prevalence | 1 | 2024 | 15717 | 0.020 |
Why?
|
| Middle Aged | 4 | 2024 | 220826 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2018 | 3425 | 0.020 |
Why?
|
| Male | 5 | 2024 | 360736 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2023 | 64651 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2024 | 12951 | 0.020 |
Why?
|
| Risk Factors | 2 | 2023 | 74167 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 14599 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 26112 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2022 | 26212 | 0.010 |
Why?
|
| Infant | 1 | 2024 | 36205 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2024 | 42254 | 0.010 |
Why?
|
| Pregnancy | 1 | 2022 | 29862 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 5127 | 0.010 |
Why?
|
| Stroke | 1 | 2018 | 9756 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 58956 | 0.010 |
Why?
|